THE MODERN DIRECTIONS OF ANTI-HELICOBACTER THERAPY
Review
DOI:
https://doi.org/10.61699/cjmps-v1-i4-p21-37Keywords:
diseases of the gastrointestinal tract, Helicobacter pylori, eradication, quadruple therapy, bismuth-containing quadruple therapyAbstract
It performed an analysis of the literature data on modern approaches to the treatment of diseases caused by Helicobacter pylori (HP), its clinical effectiveness and safety. Various treatment options are being considered: triple therapy with proton pump inhibitors (PPIs), quadruple therapy without bismuth, and bismuth-containing quadruple therapy. It is indicated that the therapeutic effectiveness of these methods, as well as their role in reducing antibiotic resistance in HP eradication, remain the subject of active debate. It is relevant to create regional databases on drug resistance, since in recent years the level of resistance to clarithromycin, metronidazole and levofloxacin has been increasing worldwide, which significantly reduces the effectiveness of traditional PPI-based triple therapy as first-line therapy. In conclusion, it is noted that the most promising fundamental principle for the treatment of HP-associated diseases is personalized therapy, the basis of which is drug sensitivity testing, since triple therapy has been found to be highly effective against the pathogen even in regions with high drug resistance.
References
Sharndama HC, Mba IE. Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms. Braz J Microbiol. 2022 Mar;53(1):33-50. doi: 10.1007/s42770-021-00675-0.
Malfertheiner P, Camargo MC, El-Omar E, Liou JM, Peek R, Schulz C, Smith SI, Suerbaum S. Helicobacter pylori infection. Nat Rev Dis Primers. 2023 Apr 20;9(1):19. doi: 10.1038/s41572-023-00431-8.
Herardi R, Syam AF, Simadibrata M, et al. Comparison of 10-day course of triple therapy versus 14-day course for eradication of Helicobacter pylori infection in an Indonesian population: double-blinded randomized clinical trial. Asian Pac J Cancer Prev 2020; 21: 19–24.
Zou Y, Qian X, Liu X, et al. The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: a systematic review and meta-analysis. Helicobacter 2020; 25: e12714.
Lee YC, Dore MP, Graham DY. Diagnosis and Treatment of Helicobacter pylori Infection. Annu Rev Med. 2022 Jan 27;73:183-195. doi: 10.1146/annurev-med-042220-020814.
Suzuki S, Kusano C, Horii T, Ichijima R, Ikehara H. The Ideal Helicobacter pylori Treatment for the Present and the Future. Digestion. 2022;103(1):62-68. doi: 10.1159/000519413
Savoldi A, Carrara E, Graham DY, et al. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization Regions. Gastroenterology 2018; 155: 1372–1382.e17.
Сhey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2017; 112: 212–239.
Dang BN and Graham DY. Helicobacter pylori infection and antibiotic resistance: a WHO high priority? Nat Rev Gastroenterol Hepatol 2017; 14: 383–384.
Shiotani A, Lu H, Dore MP, et al. Treating Helicobacter pylori effectively while minimizing misuse of antibiotics. Cleve Clin J Med 2017; 84: 310–318.
Lee JW, Kim N, Nam RH, et al. Favorable outcomes of culture-based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance. Helicobacter 2019; 24: e12561.
Choi YI, Chung JW, Park DK, et al. Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: a comparative, open trial. World J Gastroenterol 2019; 25: 6743–6751.
Sezgin O, Aydin MK, Ozdemir AA, et al. Standard triple therapy in Helicobacter pylori eradication in Turkey: systematic evaluation and meta-analysis of 10-year studies. Turk J Gastroenterol 2019; 30: 420–435.
Chang YW, Ko WJ, Oh CH, et al. Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis. Korean J Intern Med 2019; 34: 1022–1029.
Elbehiry A, Marzouk E, Aldubaib M, Abalkhail A, Anagreyyah S, Anajirih N, Almuzaini AM, Rawway M, Alfadhel A, Draz A, Abu-Okail A. Helicobacter pylori Infection: Current Status and Future Prospects on Diagnostic, Therapeutic and Control Challenges. Antibiotics (Basel). 2023 Jan 17;12(2):191. doi: 10.3390/antibiotics12020191.
Murata M, Sugimoto M, Mizuno H, et al. Clarithromycin versus metronidazole in first-line Helicobacter pylori triple eradication therapy based on resistance to antimicrobial agents: a meta-analysis. J Clin Med 2020; 9: 543.
Mabe K, Okuda M, Kikuchi S, et al. Randomized controlled trial: PPI-based triple therapy containing metronidazole versus clarithromycin as first-line treatment for Helicobacter pylori in adolescents and young adults in Japan. J Infect Chemother. 2018;24(7):538-543. doi:10.1016/j.jiac.2018.02.013
Morse AL, Goodman KJ, Munday R, et al. A randomized controlled trial comparing sequential with triple therapy for Helicobacter pylori in an Aboriginal community in the Canadian North. Can J Gastroenterol 2013; 27: 701–706.
Shiota S, Reddy R, Alsarraj A, et al. Antibiotic resistance of Helicobacter pylori among male United States Veterans. Clin Gastroenterol Hepatol. 2015; 13: 1616–1624.
Graham DY, Canaan Y, Maher J, et al. Rifabutin-based triple therapy (RHB-105) for Helicobacter pylori eradication: a double-blind, randomized, controlled trial. Ann Intern Med 2020; 172: 795–802.
Mahachai V, Vilaichone RK, Pittayanon R, et al. Helicobacter pylori management in ASEAN: the Bangkok consensus report. J Gastroenterol Hepatol 2018; 33: 37–56.
Liou JM, Chen CC, Chang CM, et al. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis 2019; 19: 1109–1120.
Myint NPST, Zaw TT, Sain K, et al. Sequential Helicobacter pylori eradication therapy in Myanmar; a randomized clinical trial of efficacy and tolerability. J Gastroenterol Hepatol 2019; 35: 617–623.
Kim BJ, Lee H, Lee YC, et al. Ten-day concomitant, 10-day sequential, and 7-day triple therapy as first-line treatment for Helicobacter pylori infection: a nationwide randomized trial in Korea. Gut Liver 2019; 13: 531–540.
Kapizioni C, Koutoufaris G, Ntouli V, et al. Optimal duration of concomitant nonbismuth quadruple therapy as first-line therapy for Helicobacter pylori: a prospective, open-label, comparative study. Eur J Gastroenterol Hepatol 2019; 31: 1206–1210.
Apostolopoulos P, Ekmektzoglou K, Georgopoulos S, et al. 10-day versus 14-day quadruple concomitant nonbismuth therapy for the treatment of Helicobacter pylori infection: results from a randomized prospective study in a high clarithromycin resistance country. J Clin Gastroenterol 2020; 54: 522–527.
Graham DY, Lee YC and Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12: 177–186.e173.
Zhou Y, Ye Z, Wang Y, et al. Comparison of four different regimens against Helicobacter pylori as a first-line treatment: a prospective, cross-sectional, comparative, open trial in Chinese children. Helicobacter 2020; 25: e12679.
Fallone CA, Moss SF and Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology 2019; 157: 44–53.
Georgopoulos SD, Xirouchakis E, Martinez Gonzales B, et al. Randomized clinical trial comparing ten-day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area. Eur J Intern Med 2016; 32: 84–90.
Hsu PI, Tsay FW, Graham DY, et al. Equivalent efficacies of reverse hybrid and bismuth quadruple therapies in eradication of Helicobacter pylori Infection in a randomized controlled trial. Clin Gastroenterol Hepatol 2018; 16: 1427–1433.
Georgopoulos SD, Papastergiou V, MartinezGonzalez B, et al. Hybrid therapy as a first-line regimen for Helicobacter pylori eradication in a high clarithromycin resistance area: a prospective open-label trial. Ann Gastroenterol 2018; 31: 205–210.
Ko SW, Kim YJ, Chung WC, et al. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: systemic review and meta-analysis. Helicobacter 2019; 24: e12565.
Alsamman MA, Vecchio EC, Shawwa K, et al. Retrospective analysis confirms tetracycline quadruple as best Helicobacter pylori regimen in the USA. Dig Dis Sci 2019; 64: 2893–2898.
Macias-Garcia F, Baston-Rey I, de la Iglesia Garcia D, et al. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter pylori infection in an area of high resistance to clarithromycin: a prospective, cross-sectional, comparative, open trial. Helicobacter 2019; 24: e12546.
Kim SJ, Chung J-W, Woo HS, et al. Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: a prospective open-label randomized trial. World J Gastroenterol 2019; 25: 6790–6798.
Castro Fernández M, Romero García T, Keco Huerga A, et al. Compliance, adverse effects and effectiveness of first-line bismuth-containing quadruple treatment (Pylera®) to eradicate Helicobacter pylori infection in 200 patients. Rev Esp Enferm Dig 2019; 111: 467–470.
Nyssen OP, McNicholl AG and Gisbert JP. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori. Helicobacter 2019; 24: e12570.
Fiorini G, Saracino IM, Zullo A, et al. Antibiotic resistance and therapy for H. pylori infection in immigrant patients treated in Italy. J Clin Med2020; 9: 1299.
Ko SW, Kim Y-J, Chung WC, et al. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: systemic review and metaanalysis. Helicobacter 2019; 24: e12565.
Graham DY and Lee SY. How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly. Gastroenterol Clin North Am 2015; 44: 537–563.
Chen Q, Long X, Ji Y, et al. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Aliment Pharmacol Ther. 2019;49(11):1385-1394. doi:10.1111/apt.15273
Bang CS, Lim H, Jeong HM, et al. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection. Gut Microbes 2020; 11: 1314–1323.
Zhang L, Lan Y, Wang Q, et al. Application of minocycline-containing bismuth quadruple therapies as first-line regimens in the treatment of Helicobacter pylori. Gastroenterol Res Pract 2019; 2019: 9251879.
Song Z, Suo B, Zhang L, et al. Rabeprazole, minocycline, amoxicillin, and bismuth as first-line and second-line regimens for Helicobacter pylori eradication. Helicobacter 2016; 21: 462–470.
Auttajaroon J, Vilaichone RK, Chotivitayatarakorn P, et al. Once-daily rabeprazole, levofloxacin, clarithromycin-MR, and bismuth for Helicobacter pylori eradication: a randomized study of 7 or 14 days (ONCE study). Helicobacter 2019; 24: e12615.
Gu L, Li S, He Y, et al. Bismuth, rabeprazole, amoxicillin, and doxycycline as first-line Helicobacter pylori therapy in clinical practice: a pilot study. Helicobacter 2019; 24: e12594.
De Francesco V. A novel hybrid first-line therapy for H. pylori eradication: results of a pilot study. J Gastrointestin Liver Dis 2019; 28: 129–130.
Gao C-P, Zhang D, Zhang T, et al. PPI amoxicillin dual therapy for Helicobacter pylori infection: an update based on a systematic review and meta-analysis. Helicobacter 2020; 25: e12692.
Tai WC, Liang CM, Kuo CM, et al. A 14-day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial. J Antimicrob Chemother 2019; 74: 1718–1724.
Zhang Y, Zhu YJ, Zhao Z, et al. Efficacy of modified esomeprazole-amoxicillin dual therapies for Helicobacter pylori infection: an open-label, randomized trial. Eur J Gastroenterol Hepatol 2020; 32: 563–568.
Yang J, Zhang Y, Fan L, et al. Eradication efficacy of modified dual therapy compared with bismuth-containing quadruple therapy as a first-line treatment of Helicobacter pylori. Am J Gastroenterol 2019; 114: 437–445.
Ozturk K, Kurt O, Celebi G, et al. High-dose dual therapy is effective as a first-line treatment for Helicobacter pylori infection. Turk J Gastroenterol. 2020; 31: 234–238.
Hori Y, Imanishi A, Matsukawa J, et al.1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 2010; 335: 231–238.
Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol. 2015; 6: e94.
Lyu Q-J, Pu Q-H, Zhong X-F, et al. Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials. Biomed Res Int 2019; 2019: 9781212.
Suzuki S, Gotoda T, Kusano C, et al. Sevenday vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut 2020; 69: 1019–1026.
Kusunoki M, Yuki M, Ishitobi H, et al. Effect of age on effectiveness of vonoprazan in triple therapy for Helicobacter pylori eradication. Intern Med 2019; 58: 1549–1555.
